ArticleCancers2022

Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial).

Pamela Baldin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.